Clinical trials: Reproductive Tract Infections
HIV Infection
Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.
TMC278 (also called rilpivirine) is a new drug being developed to treat HIV. Usually TMC278 is taken as a tablet, by mouth, once a day, but a 'long acting' formulation has been developed so the drug stays in the bloodstream for a…
- Trial name
- NCT01275443
- Testing
- 300mg TMC278LA, 150mg TMC278LA, 1200mg TMC278LA
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- St Stephens Aids Trust